{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:55:41Z","timestamp":1776711341949,"version":"3.51.2"},"publisher-location":"Cham","reference-count":14,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031722295","type":"print"},{"value":"9783031722301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-72230-1_60","type":"book-chapter","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:39:14Z","timestamp":1753875554000},"page":"337-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutation Specific Treatments for Inherited Retinal Diseases"],"prefix":"10.1007","author":[{"given":"Gareth D.","family":"Mercer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Ballios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Kertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"key":"60_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.924917","volume":"16","author":"HY Altay","year":"2022","unstructured":"Altay HY, Ozdemir F, Afghah F, Kilinc Z, Ahmadian M, Tschopp M, Agca C. Gene regulatory and gene editing tools and their applications for retinal diseases and neuroprotection: From proof-of-concept to clinical trial. Front Neurosci. 2022;16:924917. https:\/\/doi.org\/10.3389\/fnins.2022.924917.","journal-title":"Front Neurosci."},{"issue":"4","key":"60_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1080\/08820538.2021.1887903","volume":"36","author":"BG Ballios","year":"2021","unstructured":"Ballios BG, Pierce EA, Huckfeldt RM. Gene editing technology: Towards precision medicine in inherited retinal diseases. Semin Ophthalmol. 2021;36(4):176-184. https:\/\/doi.org\/10.1080\/08820538.2021.1887903.","journal-title":"Semin Ophthalmol."},{"issue":"4","key":"60_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13816810.2021.1904421","volume":"42","author":"M Bansal","year":"2021","unstructured":"Bansal M, Acharya S, Sharma S, Phutela R, Rauthan R, Maiti S, Chakraborty D. CRISPR Cas9 based genome editing in inherited retinal dystrophies. Ophthalmic Genet. 2021;42(4):365-374. https:\/\/doi.org\/10.1080\/13816810.2021.1904421. Epub 2021 Apr 6.","journal-title":"Ophthalmic Genet."},{"issue":"5819","key":"60_CR4","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1126\/science.1138140","volume":"315","author":"R Barrangou","year":"2007","unstructured":"Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007;315(5819):1709-12. https:\/\/doi.org\/10.1126\/science.1138140.","journal-title":"Science."},{"issue":"3","key":"60_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2012.3","volume":"1","author":"RW Collin","year":"2012","unstructured":"Collin RW, den Hollander AI, van der Velde-Visser SD, Bennicelli J, Bennett J, Cremers FP. Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol Ther Nucleic Acids. 2012;1(3):e14. https:\/\/doi.org\/10.1038\/mtna.2012.3.","journal-title":"Mol Ther Nucleic Acids."},{"key":"60_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2021.775330","volume":"3","author":"BL da Costa","year":"2021","unstructured":"da Costa BL, Levi SR, Eulau E, Tsai YT, Quinn PMJ. Prime Editing for Inherited Retinal Diseases. Front Genome Ed. 2021;3:775330. https:\/\/doi.org\/10.3389\/fgeed.2021.775330.","journal-title":"Front Genome Ed."},{"issue":"8","key":"60_CR7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.ymthe.2021.04.024","volume":"29","author":"K Dulla","year":"2021","unstructured":"Dulla K, Slijkerman R, van Diepen HC, Albert S, Dona M, Beumer W, Turunen JJ, Chan HL, Schulkens IA, Vorthoren L, den Besten C, Buil L, Schmidt I, Miao J, Venselaar H, Zang J, Neuhauss SCF, Peters T, Broekman S, Pennings R, Kremer H, Platenburg G, Adamson P, de Vrieze E, van Wijk E. Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations. Mol Ther. 2021;29(8):2441-2455. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.024.","journal-title":"Mol Ther."},{"key":"60_CR8","unstructured":"Editas Medicine Announces Clinical Data Demonstrating Proof Of Concept Of EDIT-101 From Phase 1\/2 BRILLIANCE Trial. Editas Medicine, Inc, Cambridge, Mass., November 17, 2022. Webpage retrieved June 18, 2023. <https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-clinical-data-demonstrating-proof>"},{"issue":"21","key":"60_CR9","doi-asserted-by":"publisher","first-page":"11542","DOI":"10.3390\/ijms222111542","volume":"22","author":"LA Martinez Velazquez","year":"2021","unstructured":"Martinez Velazquez LA, Ballios BG. The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease. Int J Mol Sci. 2021;22(21):11542. https:\/\/doi.org\/10.3390\/ijms222111542.","journal-title":"Int J Mol Sci."},{"key":"60_CR10","unstructured":"ProQR Announces Top-Line Results from Phase 2\/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10. ProQR Therapeutics, Leiden, Netherlands, February 11, 2022. Webpage retrieved June 18, 2023. <https:\/\/www.proqr.com\/press-releases\/proqr-announces-top-line-results-from-phase-23-illuminate-trial-of-sepofarsen-in-cep290-mediated-lca10>"},{"issue":"5","key":"60_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","volume":"28","author":"SR Russell","year":"2022","unstructured":"Russell SR, Drack AV, Cideciyan AV, Jacobson SG, Leroy BP, Van Cauwenbergh C, Ho AC, Dumitrescu AV, Han IC, Martin M, Pfeifer WL, Sohn EH, Walshire J, Garafalo AV, Krishnan AK, Powers CA, Sumaroka A, Roman AJ, Vanhonsebrouck E, Jones E, Nerinckx F, De Zaeytijd J, Collin RWJ, Hoyng C, Adamson P, Cheetham ME, Schwartz MR, den Hollander W, Asmus F, Platenburg G, Rodman D, Girach A. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial. Nat Med. 2022;28(5):1014-1021. https:\/\/doi.org\/10.1038\/s41591-022-01755-w.","journal-title":"Nat Med."},{"issue":"12","key":"60_CR12","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1093\/nar\/gkh703","volume":"32","author":"N Saleh-Gohari","year":"2004","unstructured":"Saleh-Gohari N, Helleday T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. 2004;32(12):3683-8. https:\/\/doi.org\/10.1093\/nar\/gkh703.","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"60_CR13","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.3390\/pharmaceutics14091842","volume":"14","author":"A Salman","year":"2022","unstructured":"Salman A, Kantor A, McClements ME, Marfany G, Trigueros S, MacLaren RE. Non-Viral Delivery of CRISPR\/Cas Cargo to the Retina Using Nanoparticles: Current Possibilities, Challenges, and Limitations. Pharmaceutics. 2022;14(9):1842. https:\/\/doi.org\/10.3390\/pharmaceutics14091842.","journal-title":"Pharmaceutics."},{"issue":"10","key":"60_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2020.1804853","volume":"29","author":"K Xue","year":"2020","unstructured":"Xue K, MacLaren RE. Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases. Expert Opin Investig Drugs. 2020;29(10):1163-1170. https:\/\/doi.org\/10.1080\/13543784.2020.1804853. Epub 2020 Sep 1.","journal-title":"Expert Opin Investig Drugs."}],"container-title":["Advances in Experimental Medicine and Biology","Atlas of Inherited Retinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-72230-1_60","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:35:10Z","timestamp":1776710110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-72230-1_60"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031722295","9783031722301"],"references-count":14,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-72230-1_60","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"31 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}